advertisement
 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 03-05-2019, 11:38 PM #7
liquidz1 liquidz1 is offline
Junior Member
 
Join Date: Feb 2017
Posts: 17
5 yr Member
liquidz1 liquidz1 is offline
Junior Member
 
Join Date: Feb 2017
Posts: 17
5 yr Member
Default

Quote:
Originally Posted by Streetlegal View Post
Hi Liqidz--are you sure about that? If you have any links to abstracts of articles I would be very interested.

Cheers
Paul
Here are the complete studies that they have ever done i think compiled into this pdf.
Just click on ''download PDF'' and you'll be able to see it.
If you do a key word search on oral within the pdf,you'll be able to see that it is effective

US2�19��4654�A1 - Treatments for diabetic symmetrical polyneuropathy
- Google Patents





Also i spoke to someone on reddit which stated that they were working on a topical drug for neuropathy which is going really well,didn't state which company or cream ,but pretty obvious :P

We are two scientists and we are walking into a bar AMA! : IAmA

Last edited by liquidz1; 03-06-2019 at 12:21 AM.
liquidz1 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
northerngal (08-19-2019)
 

Tags
distinctly, ongoing, pirenzepine, remember, sensations


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -5. The time now is 10:37 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.